Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Xiang-Qi Chen"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background:Gastric cancer (GC) is one of the major malignancies threatening human lives and health. Non-SMC condensin II complex subunit D3 (NCAPD3) plays a crucial role in the occurrence of many diseases. However, its role in GC remains unexplored.M
Externí odkaz:
https://doaj.org/article/4e21e5af0063471791a2dca8d82791c0
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Rho GTPase activating protein 10 (ARHGAP10) has been implicated as an essential element in multiple cellular process, including cell migration, adhesion and actin cytoskeleton dynamic reorganization. However, the correlation of AR
Externí odkaz:
https://doaj.org/article/bb2dc3ee46864206af08780751100158
Publikováno v:
Critical Care, Vol 24, Iss 1, Pp 1-3 (2020)
Externí odkaz:
https://doaj.org/article/b408d06c37a24378acf0a14ff35e8e9e
Publikováno v:
Journal of Cancer Research & Therapeutics; Aug2023, Vol. 19 Issue 4, p951-956, 6p
Autor:
Ge Zhang, Bo-Wen Chen, Xiao-Bo Yang, Huai-Yuan Wang, Xu Yang, Fu-Cun Xie, Xiang-Qi Chen, Ling-Xiang Yu, Jie Shi, Yin-Ying Lu, Hai-Tao Zhao
Publikováno v:
World journal of gastroenterology. 28(41)
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a form of rare primary liver cancer that combines intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma.To investigate overall survival (OS) and recurrence-free survival (RFS) afte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7569cb7bf1871d426001e571e52f388
https://pubmed.ncbi.nlm.nih.gov/36405111
https://pubmed.ncbi.nlm.nih.gov/36405111
Objective: We analyzed the clinical features and prognosis of advanced intra- and extra-pulmonary neuroendocrine carcinomas (NECs) in order to provide further guidance for the clinical treatment of small-cell lung cancer, which is a type of advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47764b39d52fdaff851dba298984b069
https://doi.org/10.21203/rs.3.rs-1089101/v1
https://doi.org/10.21203/rs.3.rs-1089101/v1
Publikováno v:
Critical Care, Vol 24, Iss 1, Pp 1-3 (2020)
Critical Care
Critical Care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8eca198ffeeec4d31249858e48e5d8c
https://doi.org/10.1186/s13054-020-03161-5
https://doi.org/10.1186/s13054-020-03161-5
Publikováno v:
International immunopharmacology. 83
Background Immune checkpoint inhibitors (ICIs) have been identified as validated medications in non-small cell lung cancer (NSCLC). However, they are often associated with immune-related adverse events (irAEs) including liver dysfunction. Therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::101387eed242270e08973b1f617397a0
https://pubmed.ncbi.nlm.nih.gov/32371246
https://pubmed.ncbi.nlm.nih.gov/32371246
Publikováno v:
Molecular Medicine Reports. 2014, Vol. 10 Issue 1, p347-352. 6p.
Publikováno v:
International Immunopharmacology. 77:105975
BACKGROUND The programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors have shown encouraging merits in non-small cell lung cancer (NSCLC) patients, however, they are often related to potentially fatal immune-related adverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50dbfdbcda9607e8dfa0a873502af6e9
https://doi.org/10.1016/j.intimp.2019.105975
https://doi.org/10.1016/j.intimp.2019.105975